Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II perioperative mFOLFOX6 with or without bevacizumab or panitumumab for resectable liver metastases from RAS wild-type colorectal cancer
2010-019238-29Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, panitumumab, fluorouracil, folinic acid and oxaliplatin in colorectal cancer (CRC) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: 1-year progression-free survival rate. Started Sep 2012; status: completed.
02
Drugs
bevacizumabpanitumumabfluorouracilfolinic acidoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-019238-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019238-29.